<DOC>
	<DOCNO>NCT01509651</DOCNO>
	<brief_summary>Although anticholinesterase reversal agent use combination anticholinergic drug half century , suggest used caution patient underlie cardiovascular disease . As sugammadex endogenous target , unlikely cause adverse cardiovascular effect . This selective relaxant binding agent specifically design encapsulate rocuronium , , therefore , promptly restore neuromuscular function regardless level NMB dose increase . Some report , however , suggest sugammadex may increase time effect patient population like elderly , patient intensive care renal failure patient . A less dynamic circulation increase transfer time effector site subject likely explanation effect . The present trial design assess safety efficacy sugammadex 2.0 mg kg-1 reversal rocuronium-induced NMB patient heart failure .</brief_summary>
	<brief_title>Sugammadex Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>age 18 yr old categorized American Society Anesthesiologists class 34 New York Heart Association class 24 ejection fraction &lt; 25 % schedule undergo elective surgery cardiac resynchronization therapy , automate implantable cardioverterdefibrillator ( ICD ) , battery replacement ICD biventricular pacemaker , general anaesthesia . expect difficult intubation anatomic reason neuromuscular disorder personal family history malignant hyperthermia know allergy medication use general anaesthesia able willing give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>antagonist neuromuscular block</keyword>
	<keyword>neuromuscular block , monitoring</keyword>
	<keyword>neuromuscular function</keyword>
</DOC>